You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
Title |
Sorafenib alone vs. sorafenib plus GEMOX as 1st-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial
|
---|---|
Published in |
British Journal of Cancer, April 2019
|
DOI | 10.1038/s41416-019-0443-4 |
Pubmed ID | |
Authors |
Eric Assenat, Georges-Philippe Pageaux, Simon Thézenas, Jean-Marie Peron, Yves Bécouarn, Jean-François Seitz, Philippe Merle, Jean-Frédéric Blanc, Olivier Bouché, Mohamed Ramdani, Sylvain Poujol, Hélène de Forges, Marc Ychou, Valérie Boige |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
Japan | 1 | 33% |
Spain | 1 | 33% |
United Kingdom | 1 | 33% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Practitioners (doctors, other healthcare professionals) | 2 | 67% |
Science communicators (journalists, bloggers, editors) | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 45 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 45 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 5 | 11% |
Other | 5 | 11% |
Student > Ph. D. Student | 4 | 9% |
Student > Bachelor | 3 | 7% |
Lecturer | 2 | 4% |
Other | 8 | 18% |
Unknown | 18 | 40% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 15 | 33% |
Nursing and Health Professions | 3 | 7% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 4% |
Biochemistry, Genetics and Molecular Biology | 1 | 2% |
Unspecified | 1 | 2% |
Other | 4 | 9% |
Unknown | 19 | 42% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 April 2019.
All research outputs
#15,039,988
of 23,140,503 outputs
Outputs from British Journal of Cancer
#9,121
of 10,516 outputs
Outputs of similar age
#207,886
of 351,526 outputs
Outputs of similar age from British Journal of Cancer
#64
of 79 outputs
Altmetric has tracked 23,140,503 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 10,516 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.7. This one is in the 11th percentile – i.e., 11% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 351,526 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 37th percentile – i.e., 37% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 79 others from the same source and published within six weeks on either side of this one. This one is in the 17th percentile – i.e., 17% of its contemporaries scored the same or lower than it.